MarketCap
Facebook
X
Telegram
Cue Biopharma Net Income | CUE
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Cue Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26.6 M | -40.7 M | -50.7 M | -53 M | -44.2 M | -44.8 M | -36.7 M | -39 M | -23.2 M | -7.66 M | -1.93 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.93 M | -53 M | -33.5 M |
Quarterly Net Income Cue Biopharma
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.18 M | -7.45 M | -8.48 M | -12.3 M | - | -8.66 M | -10.2 M | -12.3 M | - | -11 M | -13.2 M | -13.1 M | - | -11 M | -13.2 M | -14.3 M | - | -13 M | -10.3 M | -12.5 M | - | -10 M | -10.8 M | -12.8 M | - | -6.99 M | -9.52 M | -11.3 M | - | -12.6 M | -7.3 M | -7.52 M | - | -5.03 M | -4.41 M | -3.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.35 M | -14.3 M | -9.92 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
-64.9 M | $ 5.65 | 6.11 % | $ 692 M |  USA |
 |
Фармсинтез
LIFE
|
-525 M | - | - | - |  Russia |
 |
AbbVie
ABBV
|
1.82 B | $ 261.61 | 1.7 % | $ 463 B | USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 11.07 | 1.61 % | $ 3.31 B |  Canada |
 |
Agenus
AGEN
|
-3.08 M | $ 7.08 | 2.07 % | $ 211 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
1 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-115 M | - | -14.46 % | $ 27.9 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-44.2 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-70.8 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
-71.2 M | $ 5.38 | 0.28 % | $ 285 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-413 M | $ 33.41 | 0.16 % | $ 1.94 B | USA |
 |
Adagene
ADAG
|
-17.6 M | $ 3.3 | 2.94 % | $ 195 M |  China |
 |
iTeos Therapeutics
ITOS
|
-134 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-10.3 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-59.5 M | $ 24.7 | 2.05 % | $ 3.75 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-3.18 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-10.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.2 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-33.5 M | $ 5.13 | 0.1 % | $ 983 M | Canada |
 |
ADC Therapeutics SA
ADCT
|
-143 M | $ 1.09 | 2.35 % | $ 139 M |  Schweiz |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-30.4 M | - | 17.91 % | $ 11.1 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
-7.98 M | $ 5.03 | 2.65 % | $ 3.36 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
391 M | $ 27.54 | 0.04 % | $ 4.64 B | USA |
 |
AIM ImmunoTech
AIM
|
-14 M | $ 0.22 | 1.52 % | $ 356 K | USA |
 |
ADMA Biologics
ADMA
|
147 M | $ 9.18 | 0.16 % | $ 2.19 B | USA |
 |
Axcella Health
AXLA
|
-81.2 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-79.5 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-19.8 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
-54.6 M | $ 7.15 | 1.27 % | $ 312 M | USA |
 |
Baudax Bio
BXRX
|
-58.8 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
-39.6 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
-105 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
-37.2 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
-40.5 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
-141 M | - | - | $ 789 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-433 M | - | - | $ 7.29 B | USA |
 |
AC Immune SA
ACIU
|
-70.4 M | $ 2.67 | 2.6 % | $ 269 M | Schweiz |
 |
Akebia Therapeutics
AKBA
|
-5.3 M | $ 1.0 | 5.6 % | $ 257 M | USA |
 |
Alector
ALEC
|
-143 M | $ 2.17 | 1.64 % | $ 224 M | USA |
 |
Aligos Therapeutics
ALGS
|
-24.2 M | $ 5.05 | 0.96 % | $ 49.9 M | USA |